10-Q: Matinas BioPharma Reports Q3 2025 Loss, Going Concern Doubt

Matinas BioPharma Holdings, Inc. reported a net loss of $1.532 million for Q3 2025 and $8.433 million for the nine months ended September 30, 2025, with substantial doubt about its ability to continue as a going concern.

Summary

• The company reported a net loss of $1.532 million for the three months ended September 30, 2025, a decrease from $4.275 million for the same period in 2024.
• For the nine months ended September 30, 2025, the net loss was $8.433 million, significantly lower than $15.818 million for the nine months ended September 30, 2024.
• Cash and cash equivalents stood at $5.435 million as of September 30, 2025, down from $7.284 million at December 31, 2024.
• An accumulated deficit of $208.875 million was reported as of September 30, 2025.
• Management expressed substantial doubt about the company's ability to continue as a going concern beyond the next twelve months, as current cash is insufficient to fund planned operations.
• Research and Development (R&D) expenses decreased significantly to $0 for Q3 2025 (from $2.239 million in Q3 2024) and to $85 thousand for the nine months ended September 30, 2025 (from $9.057 million in 2024), primarily due to the pause of the MAT2203 development program and headcount reductions.
• General and Administrative (G&A) expenses also decreased due to cost-cutting measures, from $2.142 million in Q3 2024 to $1.577 million in Q3 2025, and from $7.067 million to $5.275 million for the nine-month periods.
• The company completed a private placement in February and April 2025, raising $3.3 million in gross proceeds from the issuance of Series C Convertible Preferred Stock and warrants.
• Warrants were reclassified from liability to equity on June 26, 2025, after an amendment to their terms, resulting in a $3.161 million loss from the change in fair value of the warrant liability prior to reclassification.
• A deemed dividend of $618 thousand was recognized in connection with the exchange of 2024 Warrants for 466,666 shares of common stock on August 15, 2025.
• Disclosure controls and procedures were deemed not effective as of September 30, 2025, due to an un-remediated material weakness in internal control over financial reporting related to non-routine transactions and indefinite-lived assets impairment assessment.

Sentiment

Score: 3

Explanation: While net losses decreased, this was largely due to a pause in the lead product development and cost-cutting, not improved operational performance. The explicit 'going concern' warning, insufficient cash for the next 12 months, and an un-remediated material weakness in internal controls are significant negative indicators, creating high uncertainty about the company's future viability.

Positives

• Net loss significantly reduced for both the three-month ($1.532 million vs $4.275 million) and nine-month ($8.433 million vs $15.818 million) periods compared to the prior year.
• Research and Development expenses decreased substantially, reflecting successful cost-cutting measures.
• General and Administrative expenses also decreased due to implemented cost-cutting initiatives.
• Successfully raised $3.3 million in gross proceeds through a private placement of preferred stock and warrants.
• Realized a gain of $110 thousand from the sale of certain unused laboratory equipment.
• Warrants were reclassified from liability to equity, removing future fair value volatility from the income statement.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern beyond the next twelve months.
• Cash and cash equivalents of $5.435 million are insufficient to fund planned operations for the next twelve months.
• The significant reduction in R&D expenses is primarily due to the *pause* of the MAT2203 development program, indicating a halt in the advancement of its lead product candidate.
• The company has an accumulated deficit of $208.875 million as of September 30, 2025.
• Negative cash flow from operating activities, with $5.502 million used during the nine months ended September 30, 2025.
• Disclosure controls and procedures were not effective due to an un-remediated material weakness in internal control over financial reporting.
• A deemed dividend of $618 thousand was recognized, reducing income available to common stockholders, due to the warrant exchange.

Risks

• The ability to complete one or more strategic transactions to monetize assets or provide value to stockholders is uncertain.
• The company's ability to raise capital when needed is not assured, and new financing may not be available on acceptable terms, or at all.
• Failure to raise capital would negatively impact the company's financial condition and its ability to pursue its business strategy and continue as a going concern.
• The company may never generate significant revenues to achieve profitability.
• Future equity raises could materially dilute the ownership interest of existing stockholders.
• Debt financing or preferred equity financing, if available, may lead to increased fixed payment obligations and restrictive covenants.
• Management's attention may be diverted by the need to secure additional financing.
• Raising funds through collaborations or licensing arrangements may require relinquishing valuable rights to technologies, future revenue streams, or product candidates.
• The company is exposed to risks from global supply chain disruptions, trade disputes, political instability, interest rate increases, and rising inflation rates.
• An un-remediated material weakness in internal control over financial reporting could result in material misstatements to financial statements.

Future Outlook

The company expects operating expenses to be lower in the near term until a licensing, sale, or similar transaction provides funding for the MAT2203 Phase 3 trial and LNC platform advancement. Research and development expenses are projected to increase if additional clinical studies or product candidates are pursued, and expenses will continue to rise upon FDA approval and commercial launch. The company anticipates incurring substantial and increasing losses for the foreseeable future and plans to fund operations through a combination of public/private equity offerings, debt financing, third-party funding, collaborations, and licensing arrangements. Existing cash and cash equivalents are not believed to be sufficient to fund operations beyond the next twelve months.

Management Comments

• "We expect operating expenses to be lower in the near term compared to recent years until such time as it is able to consummate a licensing, sale or other similar transaction with a prospective partner that will provide funding to support initiation of the Phase 3 registration trial for MAT2203 and advancement of the LNC platform delivery technology."
• "We expect that our research and development expenses will increase if it moves forward with additional clinical studies for its current product candidates and development of additional product candidates."
• "If the Company obtains U.S. Food and Drug Administration (FDA) approval for one or more of its product candidates, the Company expects that its expenses will continue to increase once the Company reaches commercial launch."
• "We expect to continue to incur substantial losses for the foreseeable future, and that these losses will be increasing."
• "While the Company believes in the viability of this strategy and believes the actions presently being taken by the Company provide the opportunity for it to continue as a going concern, there can be no assurance the Company will be successful in its implementation."
• "Our general and administrative expenses during 2025 decreased slightly compared to expenses incurred during 2024 as a result of cost-cutting measures implemented to conserve cash."
• "We believe that significant investment in product development is a competitive necessity, and we are seeking a partner to assist us in continuing to make these investments to be in a position to realize the potential of our product candidates and proprietary technologies."
• "We expect that most of our R&D expenses in the near-term, if any, will be incurred in support of MAT2203 and positioning that drug for a partnership with a well-funded and experienced third party biotech or pharmaceutical company."

Industry Context

Matinas BioPharma operates as a clinical-stage biopharmaceutical company, a sector inherently characterized by high research and development costs, extended product development timelines, and a significant reliance on external capital and strategic partnerships to advance drug candidates. The company's focus on its LNC platform delivery technology and lead candidate MAT2203 positions it within the competitive drug delivery and infectious disease therapeutic areas. The current strategy of pausing lead product development and actively seeking partners to monetize assets is a common, albeit challenging, approach for smaller biotechs facing liquidity constraints, particularly when approaching the capital-intensive Phase 3 clinical trial stage. The substantial reduction in R&D expenses due to this pause underscores the severe funding pressures prevalent in the industry for companies without commercialized products.

Comparison to Industry Standards

• The company's financial state, marked by persistent net losses, negative operating cash flow, and an explicit 'going concern' warning, is a common challenge for clinical-stage biopharmaceutical companies that have not yet achieved product commercialization.
• The strategy of seeking partnerships to fund late-stage clinical trials (like MAT2203's Phase 3) and conserve cash is a standard practice among smaller biotechs, reflecting the high capital requirements of drug development.
• The significant reduction in R&D spending, specifically the pause in MAT2203 development, indicates a more acute funding shortage compared to many well-capitalized industry peers who typically maintain consistent or increasing R&D investment to advance their pipelines.
• The disclosed material weakness in internal control over financial reporting is a governance issue that deviates from industry best practices, where robust financial controls are expected for public companies.

Corporate Governance

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity raises and uncertainty regarding the company's going concern status. The deemed dividend also reduced income available to common stockholders.
• Employees have already experienced a reduction in force, and future hiring is contingent on securing additional funding.
• Customers and patients may experience delays in accessing potential therapies due to the pause in MAT2203 development.
• Creditors face increased risk due to the company's going concern doubt and reliance on uncertain future financing.
• Suppliers and contractors, particularly those involved in R&D, may see reduced engagement due to decreased spending and the pause in development programs.

Next Steps

• Secure one or more partners to monetize MAT2203 and raise additional non-dilutive capital to support the initiation of the Phase 3 registration trial for MAT2203 and advancement of the LNC platform.
• Identify and evaluate other strategic options, including in-licensing one or more assets or seeking a merger partner.
• Continue to implement a remediation plan to address the material weakness in internal control over financial reporting, including engaging additional external accounting resources.
• Sell the remaining $70 thousand of laboratory equipment classified as held for sale prior to December 31, 2025.
• Potentially conduct further preclinical and clinical studies of MAT2203 and discover/develop additional product candidates, contingent on securing funding.
• Seek regulatory approvals for any product candidates that successfully complete clinical trials.
• Require the manufacture of larger quantities of product candidates for clinical development and potentially commercialization.
• Maintain, expand, and protect the intellectual property portfolio.
• Hire additional clinical, quality control, scientific, operational, financial, and management personnel.

Key Dates

Recommendation

The filing explicitly states 'substantial doubt exists about the Company's ability to continue as a going concern' and that current cash is insufficient for the next twelve months. The significant reduction in R&D expenses is directly linked to a 'pause' in the lead product development, indicating a critical halt in core operations. Furthermore, an un-remediated material weakness in internal controls raises serious governance concerns. While the net loss decreased, this was largely due to cost-cutting and pausing development, not improved operational performance or revenue generation. The company's future is highly dependent on securing external funding or partnerships, which are uncertain. These factors collectively present a highly unfavorable investment outlook, warranting a strong sell recommendation.

Keywords

Biopharmaceutical, Clinical-stage, Lipid Nanocrystal (LNC) platform, MAT2203, Going concern, Capital raise, Warrants, SEC filing, 10-Q, Financial results, Internal controls, Research and development, Corporate governance